Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 381

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 381
---
 |   |

The Group’s R&D
collaboration agreements are the delivery of services within the next 12 months for which the practical expedient in paragraph 121 (a)
of IFRS15 applies.

In 2023, all revenue
came from 1 customer (2022: 1 customer; 2021: 1 customer).

| Schedule of commercial segment |     |            |   |     |            |   |     |            |   |
|                                |     | 2023 £’000 |   |     | 2022 £’000 |   |     | 2021 £’000 |   |
| Customer A                     |     |        100 | % |     |        100 | % |     |        100 | % |

The Group contains one
reportable operating segment, Pipeline Research and Development (‘Pipeline R&D’). This segment seeks to develop products
using the Group’s nanomedicine and sustained release technology platforms. All the reconciliations required for segmental reporting
can be found in the primary statements.

The accounting policies
of the reportable segments are consistent with the Group’s accounting policies described in note 1.

| F-42 |

| 4 | Loss from operations |

| Schedule of loss from operations                                                               |     |      |     |            |     |            |     |            |   |
|                                                                                                |     | Note |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |   |
| Loss from operations is stated after charging/(crediting):                                     |     |      |     |            |     |            |     |            |   |
| Depreciation of property, plant and equipment                                                  |     |      |     |            |     |            |     |            |   |
| - Research and development costs                                                               |     |    9 |     |        135 |     |        162 |     |        198 |   |
| - Administrative costs                                                                         |     |    9 |     |          8 |     |         12 |     |         15 |   |
| Depreciation of right of use asset                                                             |     |      |     |            |     |            |     |            |   |
| - Research and development costs                                                               |     |    9 |     |        113 |     |        151 |     |        165 |   |
|